candesartan cilexetil has been researched along with Diabetic Angiopathies in 7 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Candesartan cilexetil (TCV-116), a potent angiotensin II (AII) receptor antagonist, has beneficial effects on hypertension as well as on heart, renal and cerebrovascular disease." | 3.71 | The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. ( Nagisa, Y; Nakagawa, S; Shintani, A, 2001) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MK | 1 |
| Chung, WB | 1 |
| Hong, SK | 1 |
| Kim, OR | 1 |
| Ihm, SH | 1 |
| Chang, K | 1 |
| Seung, KB | 1 |
| Baguet, JP | 1 |
| Asmar, R | 2 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 2 |
| Mallion, JM | 1 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Imamura, S | 1 |
| Matsumoto, T | 1 |
| Ishiwata, Y | 1 |
| Ono, Y | 1 |
| Yamamoto, K | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Goto, Y | 2 |
| Nagasaka, A | 1 |
| Senda, T | 1 |
| Itoh, M | 1 |
| Trenkwalder, P | 1 |
| Lehtovirta, M | 1 |
| Dahl, K | 1 |
| Nagisa, Y | 1 |
| Shintani, A | 1 |
| Nakagawa, S | 1 |
| Christensen, PK | 1 |
| Lund, S | 1 |
| Parving, HH | 1 |
4 trials available for candesartan cilexetil and Diabetic Angiopathies
| Article | Year |
|---|---|
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
A large scale study of angiotensin II inhibition therapy in an elderly population: the CHANCE study.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2006 |
Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1997 |
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2001 |
3 other studies available for candesartan cilexetil and Diabetic Angiopathies
| Article | Year |
|---|---|
Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.
Topics: Amlodipine; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dia | 2016 |
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood | 2001 |